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Edited by Horst FeldmannAbstract In Saccharomyces cerevisiae, the transcription fac-
tors Pdr1p and Pdr3p activate the expression of several genes,
including PDR5, SNQ2, and YOR1, which encode ATP-binding
cassette transporters that extrude dozens of antifungals with
overlapping but distinct speciﬁcity. In this study, it was observed
that growth resistance to speciﬁc Pdr5p substrates rose upon
disruption of the YOR1 or SNQ2 coding region and was accom-
panied by increased eﬄux. Similarly, resistance to Yor1p- and
Snq2p-speciﬁc substrates increased upon deletion of PDR5.
The mRNA and protein levels of the respective transporters in-
creased in parallel to drug resistance. b-Galactosidase activity
fused to the PDR5 or YOR1 promoter required the presence
of Pdr1p and its speciﬁc binding sites for the compensatory
induction, whereas Pdr3p had an inhibitory eﬀect.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In Saccharomyces cerevisiae, the pleiotropic drug-resistance
phenotype results largely from the altered expression of genes
encoding ATP-binding cassette (ABC) transporters. Massive
overproduction of eﬄux pumps in plasma membranes can be
achieved by the acquisition of single-base gain-of-function sub-
stitutions clustering in speciﬁc regions of the transcriptional
regulators PDR1 and PDR3, resulting in their constitutive
hyperactivation, reviewed in [1]. Analysis of these mutants
led to the identiﬁcation of a large number of genes involved
in multiple cellular processes regulated by these two transcrip-
tion factors [2]. These include the multidrug ABC transportersAbbreviations: ABC, ATP-binding cassette; DioC6, 3,3
0-dihexyloxa-
carbocyanine iodide; MFS, major facilitator superfamily; MUG, 4-
methylumbelliferyl b-D-galactopyranoside; ONPG, O-nitrophenyl-b-
D-galactoside; ORF, open reading frame; PDRE, pleiotropic drug-
response element
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doi:10.1016/j.febslet.2008.02.045Pdr5p, Snq2p, and Yor1p, the major facilitator superfamily
(MFS) pumps Tpo1p and Flr1p, as well as proteins involved
in lipid and cell-wall metabolism [2–8].
Although Pdr1p and Pdr3p exhibit some functional redun-
dancy, such as binding to the same pleiotropic drug-response
element (PDRE), they are engaged in response to diﬀerent
physiological or chemical activators. While PDR3 undergoes
auto-activation of its own transcription in response to mito-
chondrial defects [9,10], the rapid drug-induced expression of
a set of ABC and MFS transporters seems to depend on
PDR1. Artesunate-induced activation of TPO1 and PDR5
expression requires the PDR1 gene and shows a much weaker
dependence on PDR3 [11]. A similar regulation pattern was
observed in the induction of PDR5 and TPO1 by herbicides
[6].
The ability of diﬀerent compounds to induce the expression
of several antifungal eﬄux transporters of overlapping speciﬁc-
ity is a serious obstacle to the development of therapies which
aim to combine antifungals and pump inhibitors. We report
here the additional complication that in S. cerevisiae, inactiva-
tion of a particular multidrug transporter triggers compensa-
tory transcriptional stimulation of paralogous transporters.2. Materials and methods
2.1. Strains, media, and b-galactosidase assay
The yeast strains used in this study are listed in Table S1 (Supple-
mentary material). Yeast cells were grown on rich YPD or on synthetic
complete medium lacking the relevant auxotrophic components.
b-Galactosidase assays using O-nitrophenyl-b-D-galactoside (ONPG)
or 4-methylumbelliferyl b-D-galactopyranoside (MUG) as substrates
were performed as previously described [12].2.2. Plasmids
The plasmid pMK315-5 is a pRS315 derivative bearing the PDR5
gene [13]. pRS315::PDR1 is the pRS315 derivative with the PDR1 gene
[14]. pMK313-2 was constructed by cloning the SalI–XhoI fragment of
pEH22 [15] containing the SNQ2 gene into the SalI site of pRS313.
Centromeric PDR5, YOR1, and PDR3 b-galactosidase reporter plas-
mids were described previously [10,16].2.3. Immunological methods
Protein extracts were prepared and the protein concentration was
determined as previously described [16]. After separation by SDS–
PAGE and transfer, blots were incubated with anti-Pdr5p (gift from
Karl Kuchler) or anti-Vph1p antibody (Molecular Probes) and were
developed using the enhanced chemiluminescence detection system
(Pierce).blished by Elsevier B.V. All rights reserved.
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Total yeast RNA was isolated as described [17]. RNA was fraction-
ated and hybridized using standard procedures. The YOR1 hybridiza-
tion probe was generated by PCR from yeast genomic DNA using the
primers 5 0-ATC AAA CAT GCA CCA ATA GCG TAA CCA AT-30
and 5 0-GTG GGG GAT GCA GTT TCG GAG AC-3 0. Probes for
PDR5, SNQ2, and actin were described previously [3]. The DNA frag-
ments were radiolabeled with [a-32P]dCTP using the Radprime DNA
labeling system (Invitrogen).B
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wt Δ1 Δ2 Δ5 Δ1Δ2Δ5Δ Δ1 22.5. Fluorescence measurements
Exponentially growing cultures were collected and washed with
water. The cells were deenergized and preloaded by incubation with
5 lM 3,3 0-dihexyloxacarbocyanine iodide (DioC6) in diﬀerent buﬀers
in the presence of antimycin and deoxyglucose, similarly to the previ-
ously described procedure [13]. Preloaded cells were collected by
centrifugation and washed. Eﬄux was started by the addition of
glucose (2% ﬁnal concentration). The viability of the cells was veriﬁed
by methylene blue staining. Fluorescence was recorded with a Molec-
ular Devices Gemini EM microplate spectroﬂuorometer at 485 nm
excitation and 510 emission wavelengths.0
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Δ1Δ2Δ5Δ Δ1 22.6. Growth inhibition assays
Susceptibility of the yeast to growth inhibition was determined as
previously described [18]. Phenotypes of knockout mutants were con-
ﬁrmed by plasmid complementation and tetrad analysis.YPD + fluconazole (31 M)μ
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Fig. 1. Eﬀect of disruption of PDR5, YOR1, and SNQ2 coding regions
on tolerance to growth inhibition by azoles and by their preferential
substrates cycloheximide (Cx), oligomycin (Oli), and resazurine (Res),
respectively. (A) Inhibition of Saccharomyces cerevisiae growth by
ketoconazole (0.75 lM) and (B) ﬂuconazole (31 lM). Growth of the
isogenic wild-type strain and PDR5, YOR1, and SNQ2 knockouts was
monitored in 96-well plates by OD600 measurement. (C) Equal
amounts of a cell suspension of the wild-type (wt), as well as the
single and multiple knockouts of YOR1 (D1), SNQ2 (D2), or PDR5
(D5) were spotted on drug-containing YPG plates (concentrations in
lg/ml are indicated). Growth was observed after 2 days.3. Results and discussion
3.1. Inactivation of SNQ2 and YOR1 increases resistance to
azoles and other substrates of Pdr5p
We have previously shown that Pdr5p is the major multi-
drug resistance transporter of S. cerevisiae. It detoxiﬁes azole
antifungals and a wide variety of other compounds, many
structurally resembling membrane lipids, with some overlap
in speciﬁcity with homologous Snq2p and Yor1p [19].
Fig. 1A and B shows that ‘‘genetic inhibition’’ by disruption
of the YOR1 or SNQ2 coding sequence, increased tolerance
to ketoconazole, the eﬀect being stronger in the double mutant,
which was also more resistant to ﬂuconazole. This eﬀect de-
pends on Pdr5p, as it disappears in the triple knockout of
YOR1, SNQ2, and PDR5. Resistance to cycloheximide, which
is preferentially detoxiﬁed by Pdr5p, also increased upon dis-
ruption of YOR1 coding region and was most pronounced in
the double YOR1, SNQ2 knockout (Fig. 1C). Similar eﬀects
were also observed with compounds preferentially detoxiﬁed
by Yor1p and Snq2p. Yor1p-mediated resistance to oligomy-
cin increased in response to deletion in the PDR5 coding se-
quence (Fig. 1C), whereas Snq2p-mediated resistance to
resazurine increased upon disruption of PDR5 and YOR1.
The observed substrate speciﬁcity, which extends to other clas-
ses of compounds (data not shown), indicates that the ob-
served growth phenotypes are related to increased activity of
the corresponding transporters.3.2. Extrusion of the Pdr5p substrate increases upon inactivation
of YOR1 and SNQ2
The increased sensitivity to growth inhibition by DioC6, in a
strain with PDR5 deletion (Fig. 2A), suggested that it is a
transported substrate. An elevated transport activity of Pdr5p
upon disruption of YOR1 and SNQ2 coding regions as com-
pared to the wild-type reference strain was observed in the
newly developed ﬂuorescence-based assay using DioC6. Mea-
surement of dye eﬄux from wild-type cells, initiated by glucoseaddition to de-energized and preloaded cells was associated
with a decrease in ﬂuorescence intensity (Fig. 2B). In the ab-
sence of Pdr5p the rate of ﬂuorescence changes decreased to
the background level, also observed in the absence of glucose,
which most likely resulted from dye bleaching. This suggests
that Pdr5p is the major contributor to the active eﬄux of
DioC6 in the presence of the wild-type PDR1.
The rate of change in ﬂuorescence intensity in the double
YOR1, SNQ2 knockout increased as compared to the wild-
type strain. As expected it did not reach the level observed
in the PDR1-3 mutant in which Pdr5p is the most highly over-
produced plasma membrane transporter [20] and confers high
level of cycloheximide resistance [14].
Direct measurement of DioC6 ﬂuorescence in the cell-free
external buﬀer measured 45 min after glucose addition con-
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Fig. 3. Changes in Pdr5p and Yor1p protein levels in response to
inactivation of genes encoding homologous transporters. (A) Changes
in Pdr5p protein level in knockouts of SNQ2 (D2) and YOR1 (D1). (B)
Changes in Yor1p protein level in PDR5 (D5) and SNQ2 disruptants.
Western blotting was performed as described in experimental proce-
dures. Vph1p-speciﬁc antibodies were used as the loading control.
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Fig. 2. Inhibition of Saccharomyces cerevisiae growth by DioC6. (A)
Growth of wild-type, and disruptants of YOR1, SNQ2, PDR5 coding
regions (D1, D2, D5, respectively) was monitored in 96-well plates by
OD600 measurement. Serial dilution of DioC6 ranging from 92 lM
(bottom) to 5.7 lM (top) with twofold increments is indicated. The last
row with solvent alone serves as growth control. (B) Real-time
measurement of DioC6 eﬄux from cells with diﬀerent levels of PDR5,
YOR1, and SNQ2 expression. Presented traces are a representative of
20 independent reproducible measurements.
A. Kolaczkowska et al. / FEBS Letters 582 (2008) 977–983 979ﬁrmed that the intensity changes observed in real time in the
cell suspensions correspond to dye eﬄux. Under these condi-
tions, the addition of detergent (1% Tween 20) was necessary
to enhance the dyes ﬂuorescence, which is drastically reduced
in aqueous solutions and increases upon binding to cell mem-
branes or detergent micelles [21]. This is in agreement with the
decrease in DioC6 ﬂuorescence intensity after eﬄux from cells
during the real-time measurement (Fig. 2B). The magnitude of
eﬄux rate changes corresponded well with changes in cyclo-
heximide resistance. Similar increase in resistance to dihyd-
rosphingosine has recently been reported to be mediated by
Rsb1p-dependent eﬄux in PDR5 mutants [22]. The possible
interference of membrane potential and pH gradient in the as-
say has been excluded by its insensitivity to several ionophores
such as CCCP, nigericin, and monensin as well as gramicidin
D. Spectral analysis of the dye before and after eﬄux did
not reveal changes, indicating that it was not modiﬁed meta-
bolically.
3.3. Inactivation of YOR1, SNQ2, or PDR5 ORFs aﬀects the
mRNA and protein levels of the remaining paralogues and
induces the transcription of their own promoters
Next we veriﬁed whether increased drug resistance and eﬄux
activity was associated with alterations at the mRNA and pro-tein levels. Fig. 3A and B demonstrates that the production of
Pdr5p was elevated in response to disruption of YOR1 and
SNQ2 coding sequences and that of Yor1p increased in the
knockout of PDR5 and SNQ2. Consistently, steady-state lev-
els of PDR5 mRNA were found to be increased upon inactiva-
tion of YOR1 or SNQ2, whereas these of YOR1 or SNQ2 were
elevated when their homologues PDR5, SNQ2 or PDR5 and
YOR1 were disrupted (Fig. S1, Supplementary data).
The activity of b-galactosidase reporter plasmids reﬂected
the expression patterns seen at both the mRNA and protein
levels (Fig. 4). It also reveals that the strongest activation of
the PDR5 promoter among the single knockouts resulted from
inactivation of its own open reading frame (ORF) and that the
strong eﬀect of the combination of PDR5 and YOR1 disrup-
tions was slightly increased in the triple PDR5, SNQ2, PDR5
knockout. The YOR1 promoter responded only slightly to sin-
gle disruptions; however, a twofold increase was observed
upon inactivation of both SNQ2, PDR5 and YOR1, PDR5
coding regions, as well as in the strain carrying disruptions
of all three genes. The response of the SNQ2 promoter was
twofold in the triple YOR1, SNQ2, PDR5 knockout.
The evaluation of expression by three independent methods,
i.e. Northern blot, Western blot, and reporter gene analysis,
revealed a similar magnitude of changes and was in good
agreement with the drug phenotypes as well as transport
measurement and supported a transcriptional mechanism of
activation.
3.4. Induction requires the speciﬁc functional PDRE
The mutual compensation suggested the involvement of a
common regulatory mechanism for induction. Previous analy-
sis of the promoter regions of PDR5, YOR1, and SNQ2
revealed the presence of the common regulatory element
PDRE, which is responsible for binding and responding to
Pdr1p and Pdr3p. Detailed analysis of a plasmid-borne
PDR5 promoter fused to the lacZ reporter gene and trans-
formed into the triple disruptant of YOR1, SNQ2, PDR5 cod-
ing region as well as into the wild-type strain identiﬁed the
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Fig. 4. PDR5, YOR1, and SNQ2 promoter activity in response to
disruption of their coding sequences (D5, D1, D2, respectively).
Promoters fused in-frame with lacZ on centromeric plasmids were
introduced into the entire set of previously analyzed isogenic strains.
Transformants were grown to mid-log phase and the b-galactosidase
activity was assayed. Fold induction was calculated by division of the
mean activity in the corresponding knockout strain by the activity in
the isogenic wild-type reference (wt). Measurements were made at least
in triplicate with a standard deviation not exceeding 10% of the
measured values.
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that conserved the activity of a full length promoter in both
strains (data not shown). This region contains three of the four
PDRE elements found in the PDR5 promoter. As shown in
Fig. 5, mutations in these three Pdr1p/Pdr3p binding sites
not only drastically reduced the activity of the promoter, but
also caused a complete loss of inducibility in response to inac-
tivation of PDR5, YOR1, and SNQ2 ORFs. The lack of
induction observed with the reporter plasmid containing the
truncated PDR5 promoter with all three PDREs inactivated
by point mutations could be related to a strong decrease in
promoter activity. To resolve this alternative, two complemen-
tary approaches were used. First we veriﬁed the eﬀects of
PDRE inactivation in the YOR1 promoter, which has a more
complex regulation, less dependent on Pdr1p and Pdr3p. This
approach revealed a complete loss of YOR1 promoter induc-
ibility in response to disruptions in PDR5, YOR1, and SNQ2
coding regions when its single PDRE was mutated, while con-
serving a substantial part of its basal activity. Second, we ana-
lyzed PDR5 promoter variants with diﬀerent combinations of
mutated PDREs, which revealed diﬀerential contributions of
these sites to induction. Whereas the highest induction was
mediated by the combined activities of the second and third
PDRE, addition of the ﬁrst PDRE, which was not inducible
when present alone, decreased the response from ﬁve to three-
fold. This decrease could conceivably result from the increase
in the background of the non-inducible portion of the pro-
moter activity. However, this site had a stimulatory eﬀect oninduction when combined with either the second or third
PDRE. Although the consensus sequence of the ﬁrst and third
PDRE represents the perfect everted repeat (TCCGCGGA), in
contrast to the second PDRE (TCCGTGGA), their induction
properties are totally diﬀerent. Moreover, the spacing between
the diﬀerent PDREs is similar. This underscores the role of
neighboring sequences in the modulation of the PDRE re-
sponse, which might inﬂuence the occupancy of these sites
by diﬀerent homo and heterodimers of Pdr1p and Pdr3p as
well as other proteins. As reported by Hellauer et al. [23],
PDR5 expression is decreased by Rdr1p repressor in a
PDRE-dependent manner. The same region encompassing
the ﬁrst PDRE has also been shown to bind the activator
Stb5p, and its deletion reduced PDR5 expression [24]. We
did not, however, observe any eﬀect of either Stb5p or Rdr1p
on induction (data not shown).3.5. Induction of PDR5 in response to defects in the transporter
genes is not related to mitochondrial dysfunction
A high induction of PDR5 via the Pdr3p autoregulatory
loop in the absence of xenobiotics occurs in response to mito-
chondrial defects [9,10]. This mechanism is highly speciﬁc to
Pdr3p and is likely to be controlled by the Ssa1p/2 chaperone
[25]. The endogenous mediators of Pdr1p-dependent activation
are not known. In this study, the possible role of the Pdr3p
autoactivatory loop in the induction of PDR5 and other pro-
moters was excluded by the lack of its activation in the b-galac-
tosidase reporter gene assay (Table 1). Wild-type as well as the
triple disruptant of YOR1, SNQ2, PDR5 coding regions or the
PDR1-3 hyperactive mutant were transformed with PDR3-
lacZ and PDR1-lacZ reporter plasmids [26]. b-Galactosidase
activity did not increase in the triple YOR1, SNQ2, and
PDR5 knockout as compared to the wild-type; however, the
PDR3-lacZ, but not the PDR1-lacZ, reporter responded as ex-
pected to activation by the gain-of-function PDR1-3 mutant.
In contrast, the same PDR3-lacZ reporter exhibited a strong,
eightfold, induction in response to mitochondrial signals [26].
Interestingly, the assay revealed that both promoters exhibited
a huge diﬀerence in basal activity, that of PDR1 being 60 times
higher than that of PDR3.3.6. Pdr1p is speciﬁcally required for transmission of the signal
elicited upon inactivation of PDR5, SNQ2, and YOR1,
whereas Pdr3p is inhibitory
To examine the respective roles of Pdr1p or Pdr3p in tran-
scriptional activation in response to inactivation of PDR5,
SNQ2, and YOR1 ORFs we introduced deletions of PDR1
and also PDR3 in the wild-type and the triple YOR1, SNQ2,
PDR5 knockout. These strains were then transformed with
PDR5-lacZ or YOR1-lacZ reporter plasmids. The b-galactosi-
dase measurements revealed that the presence of the pdr3 dele-
tion did not inhibit, but rather stimulated the induction. In
contrast, a complete loss of induction was associated with
the elimination of PDR1 (Fig. 6). The Pdr1p requirement
has been conﬁrmed by complementation of this defect by plas-
mid-borne PDR1.
The demonstration that even in the absence of xenobiotics,
yeast cells compensate the inactivation of multidrug pumps
by Pdr1p-dependent transcriptional activation of paralogous
transporters of overlapping speciﬁcity suggests the existence
of still unknown functions of these proteins in addition to drug
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Fig. 5. Mapping of the induction-responsive elements in the promoters of PDR5 and YOR1 using b-galactosidase reporter plasmids. A series of 5 0
deletions and internal point mutations in the PDR5 promoter fused to the lacZ gene was assayed for the reporter activity upon transformation into
triple disruptant of YOR1, SNQ2, and PDR5 coding regions and the wild-type strain. The promoter regions used and their PDRE compositions are
indicated. X – in the PDRE box denotes a point mutation that abolishes Pdr1p and Pdr3p binding. YOR1 promoter analysis was performed because
its activity is less strictly dependent on Pdr1p and Pdr3p. Fold induction was calculated by division of the mean reporter activity in the triple
knockout of YOR1, SNQ2, and PDR5 by the activity in the wild-type. Measurements were made at least in triplicate with a standard deviation not
exceeding 10% of the measured values.
Table 1
Activity of PDR1 or PDR3 promoters driven b-galactosidase activity
(RFL/OD600)
a in wild-type strain and triple YOR1, SNQ2, PDR5
knockout (denoted as D1D2D5)
Vector PDR3-lacZ PDR1-lacZ
Wild-type 19 ± 4 39 ± 7 2478 ± 490
D1D2D5 10 ± 3 40 ± 6 2466 ± 113
PDR1-3 13 ± 2 516 ± 45 3310 ± 651
The response of PDR3 promoter to hyperactive PDR1-3 allele is used
as a positive control.
ab-Galactosidase activity is expressed in relative ﬂuorescence units/
OD600, 4-methylumbelliferyl b-D-galactopyranoside (MUG, Sigma)
was used as a substrate. Each value is the average (±S.D.) for eight
independent transformants.
PDR5-lacZ
YOR1-lacZ
ΔPDR1
ΔPDR3
ΔPDR1+vector
ΔPDR1+PDR1
1 2 3 4 5 6
Fold induction
1 1.5 2 2.5 3
Fold induction
ΔPDR1
ΔPDR3
ΔPDR1+vector
ΔPDR1+PDR1
Fig. 6. The eﬀect of PDR1 and PDR3 deletions on the induction of the
promoters of PDR5 and YOR1 using b-galactosidase reporter
plasmids. Fold induction was calculated by division of the mean
activities observed in the presence of PDR1 or PDR3 deletions (as
indicated) in the triple disruptant of YOR1, SNQ2, and PDR5 coding
regions (induced conditions) by the mean activities observed in
corresponding strains with intact PDR5, YOR1, and SNQ2 alleles
(uninduced conditions). Complementation was performed with PDR1
on centromeric vector (as indicated +PDR1 or +vector, respectively).
Note the double increase in the fold induction of the PDR5 promoter
in the absence of Pdr3p.
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to extrude endogenous metabolites. These include Tpo1p that
mediates resistance to quinidine and artesunate [11,7] but also
transports polyamines, such as spermidine, spermine, and
putrescine [27]. The role of another MDR MFS transporter
Qdr2p in K+ uptake and amino acid homeostasis has been
shown recently [28,29].
Identifying the regulatory insults upstream of Pdr1p and
unraveling their mechanism is of primary importance for
understanding the development and regulation of PDR not
only in the model yeast, but also in pathogenic fungi. Many
of the combination therapy approaches against pathogenic
Candida species target the inhibition of drug eﬄux transport-
ers. The induction of expression of CaCDR1 and CaCDR2
982 A. Kolaczkowska et al. / FEBS Letters 582 (2008) 977–983genes by an unknown mechanism, resulting from the combina-
tion therapy may lead to moderate or strong antagonism of
azoles activity against Candida albicans [30]. Studies in S. cere-
visiae indicate the key role of PDR1 and PDR3 in rapid induc-
tion of PDR5 mRNA in response to short-term drug exposure.
The induction of PDR5 by dichlorophenol, non-ionic deter-
gents, benzyl alcohol, and lysophospholipids was shown to
be dependent on the presence of both regulators [31]. Recent
microarray data and chip-on-chip analyses clearly indicate that
in the case of basal expression, the absence of PDR1 could eas-
ily be complemented by PDR3, while PDR1 is the only PDR
regulator indispensable for the early ﬂuphenazine-induced
expression of a subset of genes [32].
The fact that Triton X-100 and other polyoxyethylene-type
detergents as well as ﬂuphenazine are potent inhibitors of
Pdr5p [13,20, and our unpublished observations] and our dem-
onstration that the genetic inactivation of particular multidrug
transporters is suﬃcient to trigger the compensatory transcrip-
tional responses sheds new light on the possible mechanisms of
drug antagonism in pathogenic yeast.Acknowledgements: This work was supported in part by Grants from
the Service de la Politique Scientiﬁque, Belgium, Ministry of Scientiﬁc
Research and Information Technology (Grant 2P05A 080 28), Intra-
mural UW Research Program (Grant 2751/W/WBT/07), and NIH
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Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.
2008.02.045.References
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